# CAR T-cell Therapy Targeting CD19 and BCMA in Patients With Relapse/Refractory Autoimmune Diseases

> **NCT06941129** · PHASE1 · RECRUITING · sponsor: **Institute of Hematology & Blood Diseases Hospital, China** · enrollment: 12 (estimated)

## Conditions studied

- Systemic Lupus Erythematosus
- Systemic Sclerosis (SSc)
- Inflammatory Myopathy
- ANCA-Associated Vasculitis (AAV)
- Connective Tissue Disease-Associated Thrombocytopenia
- SLE-ITP

## Interventions

- **BIOLOGICAL:** UCAR T-cell

## Key facts

- **NCT ID:** NCT06941129
- **Lead sponsor:** Institute of Hematology & Blood Diseases Hospital, China
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-02-11
- **Primary completion:** 2028-02-18
- **Final completion:** 2028-03-18
- **Target enrollment:** 12 (ESTIMATED)
- **Last updated:** 2025-09-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06941129

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06941129, "CAR T-cell Therapy Targeting CD19 and BCMA in Patients With Relapse/Refractory Autoimmune Diseases". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06941129. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*